Eric Nisenbaum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eric Nisenbaum has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
A Eliot Shearer
Department of Otolaryngology-Head and Neck Surgery, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
1 shared publicationDenise Yan
Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA
1 shared publication- Elizabeth Nicolli
Department of Otolaryngology, University of Miami Miller School of Medicine
1 shared publication Evan de Joya
Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA
1 shared publicationHinrich Staecker
Department of Otolaryngology Head and Neck Surgery, University of Kansas Health System, Kansas City, Kansas, USA
1 shared publication- Jeffrey R. Holt
Departments of Otolaryngology & Neurology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA
1 shared publication
Latest Publications
- 5 October 2023
- Published by Springer Nature
- p. 167-181
Perioperative Nutrition in Head and Neck Free Flap Reconstruction
- 5 October 2023
- Published by Springer Nature
- p. 167-181
Perioperative Nutrition in Head and Neck Free Flap Reconstruction
- 16 June 2023
- Published by S. Karger AG in Audiology and Neurotology
- Vol. 28 (6) , 407-419
Genotype-Phenotype Correlations in TMPRSS3 (DFNB10/DFNB8) with Emphasis on Natural History
Background: Mutations in TMPRSS3 are an important cause of autosomal recessive non-syndromic hearing loss. The hearing loss associated with mutations in TMPRSS3 is characterized by phenotypic heterogeneity, ranging from mild to profound hearing loss, and is generally progressive. Clinical presentation and natural history of TMPRSS3 mutations vary significantly based on the location and type of mutation in the gene. Understanding these genotype-phenotype relationships and associated natural disease histories is necessary for the successful development and application of gene-based therapies and precision medicine approaches to DFNB8/10. The heterogeneous presentation of TMPRSS3-associated disease makes it difficult to identify patients clinically. As the body of literature on TMPRSS3-associated deafness grows, there is need for better categorization of the hearing phenotypes associated with specific mutations in the gene. Summary: In this review, we summarize TMPRSS3 genotype-phenotype relationships including a thorough description of the natural history of patients with TMPRSS3-associated hearing loss to lay the groundwork for the future of TMPRSS3 treatment using molecular therapy. Key Messages: TMPRSS3 mutation is a significant cause of genetic hearing loss. All patients with TMPRSS3 mutation display severe-to-profound prelingual (DFNB10) or a postlingual (DFNB8) progressive sensorineural hearing loss. Importantly, TMPRSS3 mutations have not been associated with middle ear or vestibular deficits. The c.916G>A (p.Ala306Thr) missense mutation is the most frequently reported mutation across populations and should be further explored as a target for molecular therapy.
- 16 June 2023
- Published by S. Karger AG in Audiology and Neurotology
- Vol. 28 (6) , 407-419
Genotype-Phenotype Correlations in TMPRSS3 (DFNB10/DFNB8) with Emphasis on Natural History
Background: Mutations in TMPRSS3 are an important cause of autosomal recessive non-syndromic hearing loss. The hearing loss associated with mutations in TMPRSS3 is characterized by phenotypic heterogeneity, ranging from mild to profound hearing loss, and is generally progressive. Clinical presentation and natural history of TMPRSS3 mutations vary significantly based on the location and type of mutation in the gene. Understanding these genotype-phenotype relationships and associated natural disease histories is necessary for the successful development and application of gene-based therapies and precision medicine approaches to DFNB8/10. The heterogeneous presentation of TMPRSS3-associated disease makes it difficult to identify patients clinically. As the body of literature on TMPRSS3-associated deafness grows, there is need for better categorization of the hearing phenotypes associated with specific mutations in the gene. Summary: In this review, we summarize TMPRSS3 genotype-phenotype relationships including a thorough description of the natural history of patients with TMPRSS3-associated hearing loss to lay the groundwork for the future of TMPRSS3 treatment using molecular therapy. Key Messages: TMPRSS3 mutation is a significant cause of genetic hearing loss. All patients with TMPRSS3 mutation display severe-to-profound prelingual (DFNB10) or a postlingual (DFNB8) progressive sensorineural hearing loss. Importantly, TMPRSS3 mutations have not been associated with middle ear or vestibular deficits. The c.916G>A (p.Ala306Thr) missense mutation is the most frequently reported mutation across populations and should be further explored as a target for molecular therapy.